Review
Biochemistry & Molecular Biology
Margaux Teil, Marie-Laure Arotcarena, Benjamin Dehay
Summary: NHP models play a crucial role in studying synucleinopathy, providing insights into its pathogenicity and contributing to the development of therapeutic strategies for the disease.
Article
Multidisciplinary Sciences
Ayano Matsushima, Sergio Sebastian Pineda, Jill R. Crittenden, Hyeseung Lee, Kyriakitsa Galani, Julio Mantero, Geoffrey Tombaugh, Manolis Kellis, Myriam Heiman, Ann M. Graybiel
Summary: In human and mouse models of Huntington's disease, the two defining axes of striatal projection neurons are mixed and differentially affected. The indirect-pathway striatal projection neurons are the most depleted in human patients, while the transcriptomic distinctiveness of striosome-matrix neurons is diminished more in mouse models. The loss of striosome-matrix distinction is more prominent within the indirect-pathway neurons, suggesting the need for distinct therapeutic strategies based on the differential compromise of these two axes.
NATURE COMMUNICATIONS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yu Iwabuchi, Tohru Shiga, Masashi Kameyama, Raita Miyazawa, Morinobu Seki, Daisuke Ito, Hiroyuki Uchida, Hajime Tabuchi, Masahiro Jinzaki
Summary: This study suggests that regional changes in striatal I-123-ioflupane accumulation on DAT-SPECT are related to brain perfusion changes in patients with LBD.
MOLECULAR IMAGING AND BIOLOGY
(2022)
Article
Clinical Neurology
Vesna Sossi, Joseph R. Patterson, Siobhan McCormick, Christopher J. Kemp, Kathryn M. Miller, Anna C. Stoll, Nathan Kuhn, Michael Kubik, Joseph Kochmanski, Kelvin C. Luk, Caryl E. Sortwell
Summary: The study investigated dopaminergic deficits in a rat model and found that there were progressive decreases in DAT density and increases in DA turnover, which resemble the alterations observed in human PD.
MOVEMENT DISORDERS
(2022)
Article
Neurosciences
Hua-Ying Cai, Xiao-Xiao Fu, Hong Jiang, Shu Han
Summary: Animal studies have shown that increased BBB permeability and inflammatory cell infiltration play a role in the progression of PD. Using C16 peptide and Ang-1 in combination has demonstrated neuroprotective and anti-inflammatory properties in PD models, showing improvements in neuronal apoptosis, cognitive impairment, electrophysiological dysfunction, and overall functional disability.
NPJ PARKINSONS DISEASE
(2021)
Article
Cell Biology
Marta M. Morawska, Carlos G. Moreira, Varun R. Ginde, Philipp O. Valko, Tobias Weiss, Fabian Buechele, Lukas L. Imbach, Sophie Masneuf, Sedef Kollarik, Natalia Prymaczok, Juan A. Gerez, Roland Riek, Christian R. Baumann, Daniela Noain
Summary: Enhancing slow-wave sleep in murine models of Parkinson's disease reduces pathological alpha-synuclein accumulation and may improve disease progression through mechanisms such as promoting glymphatic clearance.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Clinical Neurology
Tatiana Usnich, Elena Krasivskaya, Fabian Klostermann
Summary: Patients with Parkinson's disease exhibit deficits in both cognitive and affective Theory of Mind, which are not effectively countered by dopamine replacement therapy aimed at improving motor symptoms.
FRONTIERS IN NEUROLOGY
(2023)
Article
Neurosciences
Frederic Sampedro, Saul Martinez-Horta, Juan Marin-Lahoz, Javier Pagonabarraga, Jaime Kulisevsky
Summary: The study suggests that apathy in Parkinson's disease may be associated with extra-striatal dopaminergic degeneration, which in turn increases the risk of developing cognitive impairment or dementia.
JOURNAL OF PARKINSONS DISEASE
(2022)
Article
Neurosciences
Paola Imbriani, Giuseppina Martella, Paola Bonsi, Antonio Pisani
Summary: Parkinson's disease (PD) is a multifactorial disorder with genetic and environmental factors playing a part. Mitochondrial impairment and oxidative stress are important mechanisms in PD, supported by PD-associated genes involved in mitochondrial function. Dysfunction of mitochondria is closely linked to synaptic dysfunction, which is an early event before nigrostriatal neurodegeneration in PD.
NEUROBIOLOGY OF DISEASE
(2022)
Article
Multidisciplinary Sciences
J. Brucker Nourse, Shannon N. Russell, Nathan A. Moniz, Kylie Peter, Lena M. Seyfarth, Madison Scott, Han-A Park, Kim A. Caldwell, Guy A. Caldwell
Summary: This study investigates the TNK2 gene variants in Parkinson's disease (PD) patients and their potential impact on dopaminergic neurodegeneration. The findings suggest that TNK2 dysfunction may contribute to PD, possibly through sustained or aberrant activity. The study also highlights the importance of TNK2 and its ortholog SID-3 in coordinating dopaminergic and epigenetic signaling. Experimental results using Caenorhabditis elegans and rat primary neurons demonstrate the neuroprotective effects of TNK2 inhibition and NEDD4 activation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Clinical Neurology
Lukas Hensel, Aline Seger, Ezequiel Farrher, Anna K. Bonkhoff, N. Jon Shah, Gereon R. Fink, Christian Grefkes, Michael Sommerauer, Christopher E. J. Doppler
Summary: This study found that the motor response in Parkinson's disease patients is related to the temporal dynamics of corticostriatal functional connectivity. Patients with high response spent more time in a regionally integrated state, while low responders showed lower functional connectivity between the anterior midcingulate cortex/dorsal anterior cingulate cortex and putamen during a more segregated state, which was correlated with the motor response.
PARKINSONISM & RELATED DISORDERS
(2023)
Review
Biochemistry & Molecular Biology
Ezia Guatteo, Nicola Berretta, Vincenzo Monda, Ada Ledonne, Nicola Biagio Mercuri
Summary: This article focuses on the functional properties of nigral dopaminergic neurons and summarizes the shared or unique features of neuronal dysfunction in different stages of PD animal models, with the goal of illustrating the functional modifications occurring in these neurons during disease progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Neurosciences
Majken B. Thomsen, Sara A. Ferreira, Anna C. Schacht, Jan Jacobsen, Mette Simonsen, Cristine Betzer, Poul H. Jensen, David J. Brooks, Anne M. Landau, Marina Romero-Ramos
Summary: The study demonstrates that intrastriatal injection of a-syn fibrils induces progressive synaptic dysfunction and degeneration of dopamine terminals prior to cell death. PET imaging shows a gradual decrease in VMAT2 and SV2A binding in the ipsilateral striatum, while misfolded a-syn pathology spreads anatomically connected regions and becomes bilateral over time. The presence of MHCII positive ramified microglia indicates neuroinflammation in the injected striatum and substantia nigra.
NEUROBIOLOGY OF DISEASE
(2021)
Review
Neurosciences
Nikolaus Wenger, Arend Vogt, Matej Skrobot, Elisa L. Garulli, Burce Kabaoglu, Christina Salchow-Hoemmen, Thomas Schauer, Daniel Kroneberg, Michael K. Schuhmann, Christoph Harms, Matthias Endres, Ioannis U. Isaias, Philip Tovote, Robert Blum, Chi Wang Ip
Summary: This article summarizes strategies for modeling parkinsonian gait in rodents and discusses the relationship between clinical research findings and motor deficits and network oscillations in animal models. The article suggests that future research should incorporate behavioral tests with higher cognitive demands and emphasizes that basic research should benefit from evolving signal processing strategies from clinical research.
EXPERIMENTAL NEUROLOGY
(2022)
Review
Neurosciences
Maryann N. Krasko, Jesse D. Hoffmeister, Nicole E. Schaen-Heacock, Jacob M. Welsch, Cynthia A. Kelm-Nelson, Michelle R. Ciucci
Summary: Parkinson's disease is a progressive disorder affecting 10 million people worldwide, with over 90% developing hypokinetic dysarthria. Limited understanding of pathological mechanisms and treatment options has led to exploration of rat models for insights into vocal deficits.
Article
Behavioral Sciences
Philippe Huot, Tom H. Johnston, James B. Koprich, Maria C. Espinosa, Maria Gabriela Reyes, Susan H. Fox, Jonathan M. Brotchie
BEHAVIOURAL PHARMACOLOGY
(2015)
Article
Clinical Neurology
Yilong Ma, Tom H. Johnston, Shichun Peng, Chuantao Zuo, James B. Koprich, Susan H. Fox, Yihui Guan, David Eidelberg, Jonathan M. Brotchie
MOVEMENT DISORDERS
(2015)
Article
Neurosciences
Philippe Huot, Tom H. Johnston, Susan H. Fox, Adrian Newman-Tancredi, Jonathan M. Brotchie
Article
Neurosciences
Philippe Huot, Tom H. Johnston, Susan H. Fox, Jonathan M. Brotchie
Article
Neurosciences
Tom H. Johnston, Eboo Versi, Patrick A. Howson, Paula Ravenscroft, Susan H. Fox, Michael P. Hill, Bruce E. Reidenberg, Ronald Corey, Jonathan M. Brotchie
Review
Neurosciences
Tom H. Johnston, Alix M. B. Lacoste, Naomi P. Visanji, Anthony E. Lang, Susan H. Fox, Jonathan M. Brotchie
Article
Pharmacology & Pharmacy
Elizabeth F. Brigham, Tom H. Johnston, Carl Brown, Jonathon D. S. Holt, Susan H. Fox, Michael P. Hill, Patrick A. Howson, Jonathan M. Brotchie, Jack T. Nguyen
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2018)
Article
Clinical Neurology
Karen L. Eskow Jaunarajs, David G. Standaert, Tacey X. Viegas, Michael D. Bentley, Zhihao Fang, Bekir Dizman, Kunsang Yoon, Rebecca Weimer, Paula Ravenscroft, Tom H. Johnston, Michael P. Hill, Jonathan M. Brotchie, Randall W. Moreadith
MOVEMENT DISORDERS
(2013)
Article
Neurosciences
Philippe Huot, Tom H. Johnston, Katie D. Lewis, James B. Koprich, M. Gabriela Reyes, Susan H. Fox, Matthew J. Piggott, Jonathan M. Brotchie
Article
Multidisciplinary Sciences
James B. Koprich, Tom H. Johnston, Gabriela Reyes, Vanessa Omana, Jonathan M. Brotchie
Article
Clinical Neurology
Tom H. Johnston, Michal Geva, Lilach Steiner, Aric Orbach, Spyros Papapetropoulos, Juha-Matti Savola, Ian J. Reynolds, Paula Ravenscroft, Michael Hill, Susan H. Fox, Jonathan M. Brotchie, Ralph Laufer, Michael R. Hayden
MOVEMENT DISORDERS
(2019)
Article
Clinical Neurology
A. L. Barth, J. S. Schneider, T. H. Johnston, M. P. Hill, J. M. Brotchie, J. R. Moskal, Cassia N. Cearley
MOVEMENT DISORDERS
(2020)
Article
Clinical Neurology
R. Depoortere, T. H. Johnston, S. H. Fox, J. M. Brotchie, A. Newman-Tancredi
PARKINSONISM & RELATED DISORDERS
(2020)
Article
Neurosciences
Jay S. Schneider, Courtney A. Marshall, Lauren Keibel, Nathaniel W. Snyder, Michael P. Hill, Jonathan M. Brotchie, Tom H. Johnston, Barry D. Waterhouse, Sandhya Kortagere
Summary: Mild cognitive impairment in Parkinson's disease (PD-MCI) can manifest as deficits in various cognitive functions and may be an early symptom of the disease. Current pharmacological treatments are limited due to the involvement of multiple neurotransmitter systems. Developing therapeutics that can target both motor and cognitive impairments in PD is crucial for improving patient outcomes.
EXPERIMENTAL NEUROLOGY
(2021)